Teva Returns to M&A with US$3.5 B Auspex Pharma Purchase Before Making US$40 B Approach for Mylan
By Heather Cartwright & Sayani Datta
Pharma Deals Review: Vol 2015 Issue 5 (Table of Contents)
Published: 6 May-2015
DOI: 10.3833/pdr.v2015.i5.2101 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Signalling its return to M&A after a period of cost cutting, Teva Pharmaceutical Industries has agreed to acquire Auspex Pharmaceuticals and its portfolio of drug candidates for hyperkinetic movement disorders for an equity value of approximately US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS